Market Cap 2.85B
Revenue (ttm) 0.00
Net Income (ttm) -246.29M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.21
Volume 2,272,529
Avg Vol 2,775,414
Day's Range N/A - N/A
Shares Out 96.13M
Stochastic %K 32%
Beta 0.42
Analysts Strong Sell
Price Target $46.91

Company Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. Its transforming growth factor beta (TGFß) superfamily biology, its novel understanding of the molecular mechanisms of growth factor activation enabled us to develop a proprietary platform for development of monoclonal antibodies that locally and selectively targ...

Industry: Biotechnology
Sector: Healthcare
Phone: 857 259 3860
Address:
301 Binney Street, 3rd Floor, Cambridge, United States
Tdorsey1776
Tdorsey1776 Oct. 27 at 3:40 PM
$SRRK The deeper I dig the more impressed I am with the long term picture. Pipeline expansion possibilities to address other neuromuscular disorders are massive: BMD, ALS, FSHD, DMD, etc beyond the obvious obesity market. IMO the risk reward is strong with this one and as the bio M&A cycle gears up, they could be a ripe candidate soon. GLTA
0 · Reply
Thinkingman91
Thinkingman91 Oct. 27 at 1:41 PM
$SRRK I see zero resistance to $39
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 27 at 9:32 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SRRK Current Share Price: $29.68 Contracts: $SRRK January 15, 2027 $30 Calls Scale in: $8.55- $10.45 Scale out: $13.30-$17.10 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 24 at 9:18 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SRRK Current Share Price: $28.91 Contracts: $SRRK January 15, 2027 $30 Calls Scale in: $7.76- $9.49 Scale out: $12.07-$15.53 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
cheating_stock_investor
cheating_stock_investor Oct. 24 at 3:57 PM
$SRRK this company should file lawsuit to catalent and $NVO to get them to fix their issues and ask for compensation on lost time and sales. Thats the only way things will get going. They got a billion dollar drug ready to be approved plus another 1billion potential drug in the pipeline.
1 · Reply
ZackInvest008
ZackInvest008 Oct. 24 at 2:42 PM
$SRRK Decent short interest yesterday. I was looking for a rebound to 30 by EOW after that selloff but it looks like it's going to fester here longer.
0 · Reply
ZackInvest008
ZackInvest008 Oct. 23 at 5:34 PM
$SRRK Scoured the world wide web for clarification on the CLR. Looks like the plant has 6 months until the next scheduled FDA review, but can petition for sooner? Hard to pin point the scope and timeline for this aside from the Truist letter.
1 · Reply
Tdorsey1776
Tdorsey1776 Oct. 22 at 2:30 PM
$SRRK Apitegromab combo with tirzepatide (Zepbound & Mounjaro) resulted in an improved preservation of lean muscle mass of 54.9% "GLP therapies have been an effective and important innovation for individuals living with obesity and cardiometabolic disorders; however, these treatments can result in substantial loss of lean muscle mass for patients, leading to unwanted health risks," remarked Akshay Vaishnaw, Scholar Rock's president of R&D. The Phase II proof-of-concept study enrolled 102 patients with obesity or who were overweight with weight-related conditions. Patients receiving apitegromab with Zepbound lost 12.3% of their body weight after 24 weeks versus 13.4% for the arm that took Zepbound and a placebo. However, the combo arm achieved 85.3% of total weight reduction coming from fat mass, with lean mass accounting for just 14.6% of the weight lost. The placebo group saw 69.5% of the total weight reduction coming from fat and 30.2% from lean mass.
1 · Reply
Reapthewhirlwind69
Reapthewhirlwind69 Oct. 22 at 2:18 PM
$SRRK grabbed some shares yesterday and at market open this AM due to the advice of @Thinkingman91
0 · Reply
Thinkingman91
Thinkingman91 Oct. 22 at 2:17 PM
$SRRK I would like this to stop. So whatever it takes. Even a broader market dip would be welcome
0 · Reply
Latest News on SRRK
US FDA declines to approve Scholar Rock's muscle weakness drug

Sep 23, 2025, 7:12 AM EDT - 4 weeks ago

US FDA declines to approve Scholar Rock's muscle weakness drug


Scholar Rock's drug helps preserve lean mass in mid-stage trial

Jun 18, 2025, 7:12 AM EDT - 4 months ago

Scholar Rock's drug helps preserve lean mass in mid-stage trial


Scholar Rock to Participate in Upcoming Investor Conferences

Feb 25, 2025, 4:15 PM EST - 8 months ago

Scholar Rock to Participate in Upcoming Investor Conferences


Scholar Rock Highlights 2025 Strategic Priorities

Jan 8, 2025, 4:00 PM EST - 10 months ago

Scholar Rock Highlights 2025 Strategic Priorities


Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial

Oct 7, 2024, 10:10 PM EDT - 1 year ago

Scholar Rock (SRRK) Shares Surge on Successful SMA Drug Trial


Tdorsey1776
Tdorsey1776 Oct. 27 at 3:40 PM
$SRRK The deeper I dig the more impressed I am with the long term picture. Pipeline expansion possibilities to address other neuromuscular disorders are massive: BMD, ALS, FSHD, DMD, etc beyond the obvious obesity market. IMO the risk reward is strong with this one and as the bio M&A cycle gears up, they could be a ripe candidate soon. GLTA
0 · Reply
Thinkingman91
Thinkingman91 Oct. 27 at 1:41 PM
$SRRK I see zero resistance to $39
1 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 27 at 9:32 AM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SRRK Current Share Price: $29.68 Contracts: $SRRK January 15, 2027 $30 Calls Scale in: $8.55- $10.45 Scale out: $13.30-$17.10 Can Easily Capture: 60% ROI Blended DTE: 446 Days | Join Elites here: https://liquidtheta.com
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Oct. 24 at 9:18 PM
LiquidTheta® LEAPS LIVE Actionable Alert Asset: $SRRK Current Share Price: $28.91 Contracts: $SRRK January 15, 2027 $30 Calls Scale in: $7.76- $9.49 Scale out: $12.07-$15.53 Can Easily Capture: 60% ROI Blended DTE: 449 Days | Join Elites here: https://liquidtheta.com/options
0 · Reply
cheating_stock_investor
cheating_stock_investor Oct. 24 at 3:57 PM
$SRRK this company should file lawsuit to catalent and $NVO to get them to fix their issues and ask for compensation on lost time and sales. Thats the only way things will get going. They got a billion dollar drug ready to be approved plus another 1billion potential drug in the pipeline.
1 · Reply
ZackInvest008
ZackInvest008 Oct. 24 at 2:42 PM
$SRRK Decent short interest yesterday. I was looking for a rebound to 30 by EOW after that selloff but it looks like it's going to fester here longer.
0 · Reply
ZackInvest008
ZackInvest008 Oct. 23 at 5:34 PM
$SRRK Scoured the world wide web for clarification on the CLR. Looks like the plant has 6 months until the next scheduled FDA review, but can petition for sooner? Hard to pin point the scope and timeline for this aside from the Truist letter.
1 · Reply
Tdorsey1776
Tdorsey1776 Oct. 22 at 2:30 PM
$SRRK Apitegromab combo with tirzepatide (Zepbound & Mounjaro) resulted in an improved preservation of lean muscle mass of 54.9% "GLP therapies have been an effective and important innovation for individuals living with obesity and cardiometabolic disorders; however, these treatments can result in substantial loss of lean muscle mass for patients, leading to unwanted health risks," remarked Akshay Vaishnaw, Scholar Rock's president of R&D. The Phase II proof-of-concept study enrolled 102 patients with obesity or who were overweight with weight-related conditions. Patients receiving apitegromab with Zepbound lost 12.3% of their body weight after 24 weeks versus 13.4% for the arm that took Zepbound and a placebo. However, the combo arm achieved 85.3% of total weight reduction coming from fat mass, with lean mass accounting for just 14.6% of the weight lost. The placebo group saw 69.5% of the total weight reduction coming from fat and 30.2% from lean mass.
1 · Reply
Reapthewhirlwind69
Reapthewhirlwind69 Oct. 22 at 2:18 PM
$SRRK grabbed some shares yesterday and at market open this AM due to the advice of @Thinkingman91
0 · Reply
Thinkingman91
Thinkingman91 Oct. 22 at 2:17 PM
$SRRK I would like this to stop. So whatever it takes. Even a broader market dip would be welcome
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 22 at 1:46 PM
$SRRK Patience is required, the path is clear.
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 22 at 1:34 PM
$SRRK adding again this morning.
0 · Reply
JohnTill
JohnTill Oct. 22 at 1:10 AM
1 · Reply
JohnTill
JohnTill Oct. 22 at 1:10 AM
$SRRK The two things people should be talking about the most.....
0 · Reply
Thinkingman91
Thinkingman91 Oct. 21 at 10:14 PM
$SRRK there is no bear case to be made here
1 · Reply
Thinkingman91
Thinkingman91 Oct. 21 at 10:04 PM
$SRRK the more I look, the more it’s a once in a lifetime play. The valuation on this is not to be underestimated
0 · Reply
Whiskeyunderthebed
Whiskeyunderthebed Oct. 21 at 8:04 PM
$SRRK love the closing- came out of nowhere.
0 · Reply
Thinkingman91
Thinkingman91 Oct. 21 at 7:55 PM
$SRRK they gonna drop IND today I bet. That’s just a feeling though
0 · Reply
Thinkingman91
Thinkingman91 Oct. 21 at 7:52 PM
$SRRK it’s thin and getting bid up EOD
0 · Reply
Thinkingman91
Thinkingman91 Oct. 21 at 7:46 PM
$SRRK I added some today.
0 · Reply
Tdorsey1776
Tdorsey1776 Oct. 21 at 5:12 PM
$SRRK What GLP-1 player will want to differentiate their offering with far less lean muscle mass loss? with the added health benefits
1 · Reply
Tdorsey1776
Tdorsey1776 Oct. 21 at 5:10 PM
$SRRK B 1k @ $28.07 will look to add more with patience. Patience. SMA appears to be a layup once CRL is cleaned up. Pipeline of other neuromuscular disorders seems likely and their obesity combo is very attractive: apitegromab combo with tirzepatide resulted in an improved preservation of lean muscle mass of 54.9%. Im thinking $40+ by year end 2026 and higher beyond. GLTA
1 · Reply